Progress in the treatment of giant cell tumors of extremities with pathological fracture
10.3760/cma.j.cn112139-20240328-00151
- VernacularTitle:四肢骨巨细胞瘤合并病理性骨折的治疗进展
- Author:
Wenhao YAO
1
;
Daoyang FAN
;
Xieyuan JIANG
;
Weifeng LIU
Author Information
1. 首都医科大学附属北京积水潭医院骨肿瘤科 国家骨科医学中心 北京大学第四临床医学院，北京 100035
- Keywords:
Giant cell tumor of bone;
Fractures, bone;
Pathological fractures;
Treatment;
Extremities
- From:
Chinese Journal of Surgery
2025;63(1):81-85
- CountryChina
- Language:Chinese
-
Abstract:
Giant cell tumor of bone (GCTB) is a common locally aggressive junctional primary bone tumor, whose clinical treatment becomes more difficult once combined with pathological fracture. Extended curettage and en-bloc resection are common surgical procedures for treating GCTB, and drugs such as receptor activator of nuclear factor-κB ligand(RANKL) inhibitors and bisphosphonates have been successfully used. Curettage is recommended for patients with Campanaccigrade Ⅱor Campanaccigrade Ⅲ with localized soft tissue invasion only and simple fractures with intact bone structure. Resection may be considered for Campanaccigrade Ⅲ with extensive soft tissue invasion or complex fractures with incomplete bone structure. RANKL inhibitors such as denosumab may be recommended if surgery is not possible or before performing resection. This article summarizes the common treatment modalities of pathological fractures combined with giant cell tumors of extremities, including the current status of surgical and pharmacological treatments, analyzing the choice of surgical modalities in different clinical situations, in order to provide clinical inspirations for diagnosis and treatment.
